University of Hertfordshire

From the same journal

Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews

Research output: Contribution to journalArticlepeer-review

Documents

  • 3084859

    Final published version, 1.85 MB, PDF document

  • Michele Fornaro
  • Domenico De Berardis
  • Giampaolo Perna
  • Marco Solmi
  • Nicola Veronese
  • Laura Orsolini
  • Elisabetta Filomena Buonaguro
  • Felice Iasevoli
  • Cristiano André Köhler
  • André Ferrer Carvalho
  • Andrea De Bartolomeis
View graph of relations
Original languageEnglish
Article number3084859
Number of pages17
JournalBioMed Research International
Volume2017
DOIs
Publication statusPublished - 9 May 2017

Abstract

Introduction. A burgeoning number of systematic reviews considering lurasidone in the treatment of bipolar depression have occurred since its Food and Drug Administration extended approval in 2013. While a paucity of available quantitative evidence still precludes preliminary meta-analysis on the matter, the present quality assessment of systematic review of systematic reviews, nonetheless, aims at highlighting current essential information on the topic. Methods. Both published and unpublished systematic reviews about lurasidone mono- or adjunctive therapy in the treatment of bipolar depression were searched by two independent authors inquiring PubMed/Cochrane/Embase/Scopus from inception until October 2016. Results. Twelve included systematic reviews were of moderate-to-high quality and consistent in covering the handful of RCTs available to date, suggesting the promising efficacy, safety, and tolerability profile of lurasidone. Concordance on the drug profile seems to be corroborated by a steadily increasing number of convergent qualitative reports on the matter. Limitations. Publication, sponsorship, language, citation, and measurement biases. Conclusions. Despite being preliminary in nature, this overview stipulates the effectiveness of lurasidone in the acute treatment of Type I bipolar depression overall. As outlined by most of the reviewed evidence, recommendations for future research should include further controlled trials of extended duration.

Notes

Copyright © 2017 Michele Fornaro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ID: 12009643